SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Quarterly research and administrative expenses rose, while four-year BIM-IOL follow-up showed 86% of patients remained off pressure-lowering drops.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SpyGlass Pharma (Nasdaq: SGP) reported a third-quarter net loss of $24.253 million alongside clinical progress and an acquisition expanding manufacturing capacity. The loss compared with $9.816 million a year earlier; loss per share narrowed to $0.73 from $4.53. Cash, cash equivalents and short-term investments totaled $215.8 million at September 30, which the company expects to fund planned operations through 2028.
In October, SpyGlass acquired Advanced Vision Science for approximately $13 million cash, securing intraocular lens manufacturing capacity. Four-year first-in-human BIM-IOL data showed a 37% reduction in mean eye pressure across all doses, with 86% of patients off pressure-lowering drops and no product-related adverse events reported to date. The company expects Phase 3 enrollment completion in 2027. First implantations in the BIM-DRS first-in-human trial were completed in October.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.$215.8 million in cash and investments at September 30 is expected to fund planned operations through 2028.
- Moderate pointAdvanced Vision Science acquisition secured scalable commercial intraocular lens manufacturing capacity for SpyGlass.
- Minor pointFour-year BIM-IOL follow-up showed 37% lower mean eye pressure across all doses; 86% remained off pressure-lowering drops.
- Minor pointFour-year BIM-IOL vision results showed 90% maintained best corrected distance vision of at least 20/25.
- Minor pointBIM-IOL first-in-human safety showed no product-related adverse events reported to date.
7 minor points
- Minor point12-month Phase 1/2 results showed 98% receiving the intended commercial BIM-IOL dose eliminated topical eye drops.
- Minor pointPhase 1/2 visual performance improved, with mean best corrected distance vision of 86 letters, equivalent to 20/20.
- Minor pointPhase 1/2 endothelial cell loss following BIM-IOL implantation was consistent with routine cataract surgery.
- Minor point. Forward-looking: it has not happened yet and may not happen.BIM-IOL Phase 3 enrollment remains on track, with completion expected in 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.BIM-DRS first implantations were completed in October; preliminary safety and eye-pressure efficacy data are anticipated in 2027.
- Minor pointThird-quarter interest income increased to $1.992 million from $1.285 million in 2025.
- Minor pointNine-month interest income increased to $5.686 million from $2.033 million in 2025.
Negative
- Moderate pointThird-quarter net loss widened to $24.253 million from $9.816 million; per-share loss narrowed to $0.73 from $4.53.
- Moderate pointAVS acquisition cash cost was approximately $13 million in October. 1.1% of market cap
- Minor pointThird-quarter research and development expense rose to $10.034 million from $8.093 million in 2025.
- Minor pointThird-quarter general and administrative expense rose to $16.211 million from $3.008 million in 2025.
- Minor pointNine-month net loss widened to $57.935 million from $27.314 million; per-share loss narrowed to $2.00 from $12.28.
2 minor points
- Minor pointNine-month research and development expense rose to $29.518 million from $21.478 million in 2025.
- Minor pointNine-month general and administrative expense rose to $34.103 million from $6.343 million in 2025.
News Explained
At
Key Figures
- Mean IOP reduction
- 37%
- Four-year BIM-IOL FIH follow-up, across all dose levels
- Patients off topical drops
- 86%
- Four-year BIM-IOL FIH follow-up
- Patients maintaining visual acuity
- 90%
- Maintained ≥20/25 BCDVA in the four-year follow-up
- Cash, cash equivalents and short-term investments
- $215.8 million
- As of September 30, 2026
- Expected funding runway
- Through 2028
- Planned operations
- Phase 3 enrollment completion
- 2027
- BIM-IOL registrational trials
- Net loss
- $24.3 million
- Third quarter 2026
- Designed drug delivery duration
- Up to seven years
- BIM-DRS system
Previous Earnings Reports
-
Reported cash expected to fund operations through 2028 and Phase 3 enrollment remained on track.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
iol medical
iop medical
fih medical
505(b)(2) new drug application regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Acquired Advanced Vision Science, Inc. (AVS), securing scalable commercial intraocular lens (IOL) manufacturing capacity for its Phase 3 lead product candidate the Bimatoprost Drug Pad-IOL System (BIM-IOL System) and accelerating premium IOL portfolio expansion capability.
- Announced groundbreaking four-year first-in-human (FIH) efficacy and safety follow-up data of the BIM-IOL System, with a
37% reduction in mean intraocular pressure (IOP) across all dose levels and86% of patients remaining off all topical IOP-lowering drops. - Enrollment remains on track in the registrational Phase 3 trials of the BIM-IOL System, with completion expected in 2027.
- Announces completion of first implantations in the FIH study of the Bimatoprost-Drug Ring System (BIM-DRS), a non-IOL-based sustained drug delivery system for glaucoma designed to deliver up to seven years of bimatoprost.
- Cash, cash equivalents and short-term investments of
$215.8 million on September 30, 2026, are expected to fund planned operations through 2028.
IRVINE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the third quarter ended September 30, 2026.
“SpyGlass Pharma continued to execute our objectives over the course of the quarter as we aim to alter the treatment paradigm for glaucoma patients. Our underlying sustained drug delivery platform delivered four years of safety and efficacy results in the FIH trial of the BIM-IOL System, demonstrating that it can control IOP with unprecedented durability. In parallel, enrollment in our Phase 3 trials of the BIM-IOL System remains on track, and we have secured long-term commercial manufacturing supply of the IOL for the BIM-IOL System and have become a supplier of other world-class IOLs,” stated Patrick Mooney, chief executive officer of SpyGlass Pharma. “We are pleased to announce that our BIM-DRS is now in the clinic, with successful implantations of the next-generation drug delivery system in glaucoma patients who have had prior cataract surgery.”
Corporate Highlights
Acquisition of Advanced Vision Science, Inc. In October, SpyGlass Pharma acquired all the outstanding shares of common stock of AVS, an ophthalmic medical device company and manufacturer of IOLs and lens materials, for approximately
Announced Four-Year BIM-IOL FIH Efficacy and Safety Follow-Up Data. In October, SpyGlass Pharma announced groundbreaking four-year follow-up data of its FIH study of the BIM-IOL System, which demonstrated that
Presentation of Detailed Phase 1/2 Data from the BIM-IOL System Clinical Program at the American Academy of Ophthalmology (AAO) Annual Meeting. In October, Jeffrey Kammer, M.D., associate professor of ophthalmology at Vanderbilt University, presented topline 12-month Phase 1/2 data at AAO in New Orleans. The detailed 12-month safety and efficacy results reinforced the sustained IOP reduction at that timepoint, and the elimination of topical eye drops for
Completed First Implantations of the BIM-DRS in FIH Trial. In October, SpyGlass Pharma successfully completed first implantations of its next-generation drug delivery platform in the FIH trial of the BIM-DRS. BIM-DRS is a non-IOL-based system that is implanted in the ciliary sulcus and available to all ophthalmic surgeons, designed to deliver bimatoprost for up to seven years with removal and replacement capability to deliver lifetime IOP control without the burden of daily eye drops. Importantly, BIM-DRS represents the expansion of SpyGlass Pharma’s drug delivery technology beyond traditional cataract surgery and has the potential to provide continuous care over the lifetime of a patient. SpyGlass Pharma anticipates providing preliminary safety and IOP-lowering efficacy data for the BIM-DRS FIH trial in 2027.
Third Quarter 2026 Financial Results
Cash, Cash Equivalents and Short-Term Investments totaled
Research and Development Expenses were
General and Administrative Expenses were
Net Loss was
About the Bimatoprost Drug Pad-IOL System
SpyGlass Pharma’s lead product candidate, the BIM-IOL System, comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, was designed to be implanted during routine cataract surgery to reduce elevated IOP in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT). The BIM-IOL System being evaluated in ongoing Phase 3 clinical trials is designed to consistently deliver three years of bimatoprost, a prostaglandin analog approved for topical use by the U.S. Food and Drug Administration (FDA) in 2001, for the reduction of elevated IOP in patients with OAG or OHT.
SpyGlass Pharma continues long-term follow-up of patients in both the FIH trial and Phase 1/2 trial as well as patient enrollment in ongoing Phase 3 clinical trials. SpyGlass Pharma plans to work with the FDA to advance the program through 505(b)(2) New Drug Application (NDA) submission and ultimately to potential commercial approval.
About the Bimatoprost-Drug Ring System
BIM-DRS is a novel, non-bioerodible, non-IOL-based, sustained-release implant, designed to consistently deliver up to seven years of bimatoprost. BIM-DRS is implanted in a standalone procedure in the ciliary sulcus space, offering extended care for pseudophakic eyes with OAG or OHT and enabling retreatment of patients who have previously received the BIM-IOL System. BIM-DRS is engineered to be a removable and replaceable system, potentially allowing for continuous care over a patient’s lifetime.
About SpyGlass Pharma
SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.
The Company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The terms "lasting," "long-term," and "enduring" refer to being able to control IOP for years with one procedure compared to current eye drops, which require dosing daily or even more frequently. All statements in this press release that are not purely historical are forward-looking statements, including, but not limited to, statements regarding: the potential benefits and impact of SpyGlass Pharma’s portfolio on patients, including the potential to provide lasting IOP reduction, anticipated presentation of additional data, SpyGlass Pharma’s plans relating to the Phase 3 clinical development of the BIM-IOL System toward enrollment completion and clinical development of BIM-DRS, the anticipated benefits of SpyGlass Pharma’s acquisition of AVS; and the potential commercial launch and market adoption of the BIM-IOL System after FDA approval. The forward-looking statements contained herein are based upon SpyGlass Pharma’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in the Risk Factors section of the Company’s Quarterly Report on Form 10-Q for the three and nine month period ended September 30, 2026 expected to be filed with the Securities and Exchange Commission on November 12, 2026, and in similar disclosures set forth in the other documents that SpyGlass Pharma has filed and may file from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and SpyGlass Pharma assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. SpyGlass Pharma’s views in these forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Media Contact:
Nami Surendranath
+1 (402) 507-6757
nami.surendranath@omc.com
Investor Contact:
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
investors@spyglasspharma.com
| SpyGlass Pharma, Inc. | |||||||||||||||
| Condensed Balance Sheets | |||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses | |||||||||||||||
| Research and development | $ | 10,034 | $ | 8,093 | $ | 29,518 | $ | 21,478 | |||||||
| General and administrative | 16,211 | 3,008 | 34,103 | 6,343 | |||||||||||
| Total operating expenses | 26,245 | 11,101 | 63,621 | 27,821 | |||||||||||
| Loss from operations | (26,245 | ) | (11,101 | ) | (63,621 | ) | (27,821 | ) | |||||||
| Other income | |||||||||||||||
| Interest income | 1,992 | 1,285 | 5,686 | 2,033 | |||||||||||
| Change in fair value of redeemable convertible preferred stock tranche liability | - | - | - | (1,526 | ) | ||||||||||
| Total other income | 1,992 | 1,285 | 5,686 | 507 | |||||||||||
| Loss before income tax | (24,253 | ) | (9,816 | ) | (57,935 | ) | (27,314 | ) | |||||||
| Income tax provision | - | - | - | - | |||||||||||
| Net loss and comprehensive loss | $ | (24,253 | ) | $ | (9,816 | ) | $ | (57,935 | ) | $ | (27,314 | ) | |||
| Net loss per share | |||||||||||||||
| Weighted average common stock outstanding, basic and diluted | 33,451,025 | 2,166,976 | 28,989,007 | 2,224,482 | |||||||||||
| Net loss per share, basic and diluted | $ | (0.73 | ) | $ | (4.53 | ) | $ | (2.00 | ) | $ | (12.28 | ) | |||
| SpyGlass Pharma, Inc. | |||||||
| Condensed Statements of Operations | |||||||
| (in thousands, except share and per share data) | |||||||
| (unaudited) | |||||||
| September 30, 2026 | December 31, 2025 | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 208,687 | $ | 96,358 | |||
| Short-term investments | 7,072 | 11,078 | |||||
| Other receivables | 574 | 431 | |||||
| Prepaid expenses and other current assets | 1,582 | 901 | |||||
| Total current assets | 217,915 | 108,768 | |||||
| Other non-current assets | 689 | 492 | |||||
| Property and equipment, net | 6,344 | 2,339 | |||||
| Deferred offering costs | - | 2,715 | |||||
| Right-of-use asset | 1,401 | 1,552 | |||||
| Total assets | $ | 226,349 | $ | 115,866 | |||
| Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 5,649 | $ | 2,696 | |||
| Payroll-related accruals | 2,508 | 2,182 | |||||
| Other current liabilities | 6,140 | 3,706 | |||||
| Total current liabilities | 14,297 | 8,584 | |||||
| Lease liability, non-current | 1,609 | 1,582 | |||||
| Total liabilities | 15,906 | 10,166 | |||||
| Commitments and contingencies | |||||||
| Redeemable convertible preferred stock, $.00001 par value; 0 shares authorized, issued and outstanding as of September 30, 2026; 116,618,581 shares authorized, 20,341,968 shares issued and outstanding as of December 31, 2025 (aggregate liquidation preference of | - | 204,537 | |||||
| Stockholders' equity (deficit) | |||||||
| Preferred stock, $.00001 par value; 200,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2026; 0 shares authorized, issued, and outstanding as of December 31, 2025 | - | - | |||||
| Common stock, $.00001 par value; 1,000,000,000 shares authorized, 33,457,450 shares issued and outstanding as of September 30, 2026; 154,383,336 shares authorized; 2,203,620 shares issued and outstanding as of December 31, 2025 | - | - | |||||
| Common stock additional paid-in capital | 373,108 | 5,893 | |||||
| Accumulated deficit | (162,665 | ) | (104,730 | ) | |||
| Total stockholders' equity (deficit) | 210,443 | (98,837 | ) | ||||
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $ | 226,349 | $ | 115,866 | |||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were SpyGlass Pharma's third-quarter 2026 financial results?
SpyGlass reported a $24.253 million net loss, compared with $9.816 million in the third quarter of 2025. Basic and diluted loss per share was $0.73 versus $4.53. Weighted-average common shares outstanding were 33,451,025, compared with 2,166,976 a year earlier.
What did SpyGlass Pharma's four-year BIM-IOL study show?
The first-in-human follow-up showed a 37% reduction in mean eye pressure across all doses, with 86% of patients remaining off topical pressure-lowering drops. Additionally, 90% maintained best corrected distance vision of at least 20/25, and no product-related adverse events had been reported to date.
When does SpyGlass Pharma expect initial BIM-DRS clinical data?
SpyGlass anticipates preliminary safety and eye-pressure-lowering efficacy data in 2027 from the BIM-DRS first-in-human trial. The system is designed to deliver bimatoprost for up to seven years and to be removable and replaceable; that duration is a design objective, not a reported clinical result.
Why did SpyGlass Pharma's third-quarter 2026 expenses increase?
SpyGlass attributed higher research and development expenses primarily to clinical personnel hiring and continued BIM-IOL Phase 3 enrollment, while higher general and administrative expenses primarily reflected professional service fees and personnel costs.